Emerging Pharmaceutical Market - Czech Republic - Planned Healthcare Reform Plans Forecast to Slow Growth Rates



Summary



GBI Research’s new report, “Emerging Pharmaceutical Market - Czech Republic - Planned Healthcare Reform Plans Forecast to Slow Growth Rates” provides in-depth analysis of trends, issues and challenges in the pharmaceutical market in the Czech Republic. The report analyzes overall pharmaceutical and outsourcing market structure in the Czech Republic. The report provides competitive benchmarking for the leading companies and analyzes the M&A and strategic partnerships that shape the Czech pharmaceutical market. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GBI Research’s team of industry experts.

The Czech Republic pharmaceutical market is one of the most attractive markets in Central and Eastern Europe. The availability of cost effective skilled labour, high quality infrastructure and EU harmonious regulations are the main reasons for the fast growth of the Czech pharmaceutical industry. Most local drug manufacturers and distributors are owned by big international pharmaceutical firms. GBI Research valued the Czech pharmaceutical market at $3.1 billion in 2010, which grew with a compound annual growth rate (CAGR) of 11.7% from 2004 to 2010. The Czech healthcare sector will witness many new healthcare reforms in the coming years, with the primary objective of reducing growing drug expenditure. In response to these healthcare policies, the Czech pharmaceutical market is expected to witness a lower growth rate in forecast period.

GBI Research has analyzed that in 2011, generics had a share of over 50% of the Czech pharmaceutical market. Czech government reforms encourage the manufacture and use of generic drugs, in an attempt to limit drug expenditure and provide low cost-effective public healthcare. Government healthcare policies, coupled with numerous active generic manufacturing companies in the country, will increase the share of generics in the market during the forecast period.

The Czech Republic is showing a moderate recovery from the economic downturn in 2009; increased industrial outputs and government structural reforms in various sectors including healthcare have contributed to the growth. GBI Research analyzed that the new healthcare reform policy which is expect to be implemented from 2012, with elements of “standard” and “above standard” care, in which patients pay more for above standard (expensive drugs and services) care and an increase in co-payments from the patients, reduces healthcare affordability for individual patients and will pose a major challenge to the Czech pharmaceutical market.



Scope


- Overall pharma, biotech and outsourcing market structure in Czech Republic
- Czech Republic pharmaceutical market characterization, including market size, major regulatory bodies, pricing and reimbursement issues, major distribution channel and intellectual property rights.
- Czech Republic CRO market growth.
- Analysis of the leading segments within the Czech Republic pharmaceutical industry.
- Key market drivers and restraints that have a significant impact on the Czech Republic pharmaceutical market.
- Competitive benchmarking of leading companies in pharmaceutical and CRO markets.
- Key M&A activities and strategic partnership deals that have taken place between 2009 and mid 2011.



Reasons to buy


- Develop market entry and market expansion strategies by identifying the leading emerging markets poised for strong growth.
- Devise a more tailored country strategy through the understanding of key drivers and barriers of the country’s pharmaceutical market.
- Develop key strategic initiatives by understanding the key focus areas of leading companies.
- Accelerate and strengthen your market position by identifying key companies for mergers, acquisitions and strategic partnerships.

Table Of Contents

1 Table of Contents
1 Table of Contents 3
1.1 List of Tables 5
1.2 List of Figures 6
2 Emerging Pharmaceutical Market - Czech Republic - Introduction 8
2.1 GBI Research Report Guidance 8
3 Emerging Pharmaceutical Market - Czech Republic - Industry Characterstics 9
3.1 Market Size and Market Forecast 9
3.2 Market Share by Indication 10
3.3 Branded versus Generic Share 11
3.4 RandD Expenditure Innovations 11
3.5 Top Pharmaceutical Companies 14
3.6 Foreign Direct Investment 17
3.7 Marketing Distribution Channel 18
3.8 Exports and Imports 20
3.8.1 Exports 20
3.8.2 Imports 21
3.9 Market Drivers and Restraints 22
3.9.1 Drivers 22
3.9.2 Restraints 23
3.10 Industry Analysis 24
4 Emerging Pharmaceutical Market - Czech Republic - Macroeconomic Environment 25
4.1 Demographic Analysis 25
4.1.1 Population Size, Growth, and Structure 25
4.1.2 Disease Overview in Czech Republic 30
4.2 GDP 35
4.3 Per Capita Income 39
4.4 Healthcare Expenditure 40
4.4.1 Context 40
4.4.2 Analytical Framework 42
4.5 Healthcare Infrastructure 43
4.5.1 Context 43
4.5.2 Analytical Framework 44
5 Emerging Pharmaceutical Market - Czech Republic - Healthcare Regulation 47
5.1 Pharmaceutical Regulation in Czech Republic 47
5.1.1 Healthcare System Structure 47
5.1.2 Recent Healthcare Reform Plans 47
5.2 Intellectual property Rights (IPR) and entry of Generics 48
5.3 Health Insurance Coverage 49
5.3.1 Public Insurance Coverage 50
5.3.2 Private Insurance Coverage 50
5.4 Pricing and Reimbursement 50
5.4.1 Pricing 51
5.4.2 Reimbursement 51
5.5 New Drug Approval Process 52
5.6 Clinical Trials 53
5.7 Regulatory Bodies 55
6 Emerging Pharmaceutical Market - Czech Republic - Industry Trends 56
6.1 Mergers and Acquisitions 56
6.1.1 Deals by Year 56
6.1.2 Deals by Type 57
6.1.3 Deal by Value 58
6.1.4 Top MandA Deals 59
6.2 Licensing Agreements 60
6.2.1 Deals by Year 60
6.2.2 Top Three Licensing Deals 61
7 Emerging Pharmaceutical Market - Czech Republic - CRO Industry 62
7.1 Clinical Research Organization (CRO) 62
7.2 CRO Company Profiles - Foreign Players 62
7.2.1 Quintiles 62
7.2.2 PPD 64
7.2.3 Covance 65
7.2.4 Inc Research 66
7.2.5 PAREXEL 67
7.2.6 Chiltern 68
7.2.7 MEDPACE 69
7.2.8 PRA International 70
7.3 CRO Company Profiles - Domestic Players 71
7.3.1 CEPHA 71
7.3.2 KCR 72
7.3.3 A-Pharma 73
7.3.4 EastHORN 74
7.3.5 Prague Clinical Services 75
7.3.6 PHARMNET 76
8 Emerging Pharmaceutical Market - Czech Republic - Appendix 77
8.1 Market Definitions 77
8.2 Abbreviations 77
8.3 Research Methodology 77
8.3.1 Industry Performance 78
8.3.2 Macroeconomic Environment 78
8.3.3 Healthcare Regulations 78
8.3.4 Industry Trends 78
8.4 Contact Us 78
8.5 Disclaimer 78
8.6 Sources 79

1.1 List of Tables
Table 1: Emerging Pharmaceutical Market - Czech Republic, Revenue, $bn, 2004 - 2010 9
Table 2: Emerging Pharmaceutical Market - Czech Republic, Revenue Forecast, $bn, 2010 - 2018 9
Table 3: Emerging Pharmaceutical Market - Czech Republic, Government Budget Expenditure on Healthcare RandD, $m, 2004-2010 12
Table 4: Emerging Pharmaceutical Market - Czech Republic, Pharmaceutical Companies’ Expenditure on RandD, $m, 2003-2009 13
Table 5: Emerging Pharmaceutical Market - Czech Republic, FDI Inflows and Outflows for Pharmaceuticals and related Medicinal Chemicals, $m, 2004-2009 17
Table 6: Emerging Pharmaceutical Market - Czech Republic, Number of Pharmacies and Outlets, 2004-2010 18
Table 7: Emerging Pharmaceutical Market - Czech Republic, Medicinal and Pharmaceutical Products Exports, $m, 2004- 2010 20
Table 8: Emerging Pharmaceutical Market - Czech Republic, Medicinal and Pharmaceutical Products Imports, $m, 2004- 2010 21
Table 9: Emerging Pharmaceutical Market - Czech Republic, Population Forecast of Czech Republic ,Thousands, 2005 - 2050 25
Table 10: Emerging Pharmaceutical Market - Czech Republic, Population by Gender, Thousands, 2000 - 2009 27
Table 11: Emerging Pharmaceutical Market - Czech Republic, Infant Mortality Rate (Number of deaths/1,000 live births) 2000 - 2010 29
Table 12: Emerging Pharmaceutical Market - Czech Republic, Number of Deaths by Major Diseases (%), 2010 30
Table 13: Emerging Pharmaceutical Market - Czech Republic, Population Forecast for Cardiovascular Diseases (‘000), 2010-2018 31
Table 14: Emerging Pharmaceutical Market - Czech Republic, Population Forecast for Cancer (‘000), 2010-2018 32
Table 15: Emerging Pharmaceutical Market - Czech Republic, Population Forecast for Respiratory Diseases (‘000), 2010-2018 33
Table 16: Emerging Pharmaceutical Market - Czech Republic, Population Forecast for Diabetes (‘000), 2010-2018 34
Table 17: Emerging Pharmaceutical Market - Czech Republic, GDP at Market Prices, $bn, 2005-2010 35
Table 18: Emerging Pharmaceutical Market - Czech Republic, GDP Growth Rate and Inflation Rates in Czech Republic, 2005-2010 35
Table 19: Emerging Pharmaceutical Market - Czech Republic, Per Capita Income, $, 2000 - 2010 39
Table 20: Emerging Pharmaceutical Market - Czech Republic, Healthcare Expenditure, $bn, 2000-2010 41
Table 21: Emerging Pharmaceutical Market - Czech Republic, Comparative Government and Private Healthcare Expenditure, 2000 - 2008 42
Table 22: Emerging Pharmaceutical Market - Czech Republic, Comparative Healthcare Expenditure, 2000 - 2008 42
Table 23: Emerging Pharmaceutical Market - Czech Republic, Healthcare Establishments Distribution (%), 2010 43
Table 24: Emerging Pharmaceutical Market - Czech Republic, Public and Private Healthcare Establishments and Professionals Distribution, %, 2010 44
Table 25: Emerging Pharmaceutical Market - Czech Republic, Bed Distribution in Healthcare Establishments, Czech Republic (%), 2010 45
Table 26: Emerging Pharmaceutical Market - Czech Republic, Health Insurance Coverage on Healthcare Expenditure, $m, 2006- 2010 49
Table 27: Emerging Pharmaceutical Market - Czech Republic, Deals Landscape, MandA Deals, 2011 59
Table 28: Emerging Pharmaceutical Market - Czech Republic, Licensing Deals by Year, 2011 61

1.2 List of Figures
Figure 1: Emerging Pharmaceutical Market - Czech Republic, Revenue Forecast, $bn, 2004 - 2018 9
Figure 2: Emerging Pharmaceutical Market - Czech Republic, Market Share by Therapy Area(%), 2010 10
Figure 3: Emerging Pharmaceutical Market - Czech Republic, Branded versus Generic Share in Terms of Value(%), 2010 11
Figure 4: Emerging Pharmaceutical Market - Czech Republic, Government Budget Expenditure on Healthcare RandD, $m, 2004-2010 12
Figure 5: Emerging Pharmaceutical Market - Czech Republic, Pharmaceutical Companies’ Expenditure on RandD, $m, 2003-2009 13
Figure 6: Emerging Pharmaceutical Market - Czech Republic, Number of Pharmacies and Outlets, 2004-2010 18
Figure 7: Emerging Pharmaceutical Market - Czech Republic, Distribution of Pharmacies by Owner (%), 2010 19
Figure 8: Emerging Pharmaceutical Market - Czech Republic, Medicinal and Pharmaceutical Products Exports, $m, 2004- 2010 20
Figure 9: Emerging Pharmaceutical Market - Czech Republic, Medicinal and Pharmaceutical Products Imports, $m, 2004- 2010 21
Figure 10: Emerging Pharmaceutical Market - Czech Republic, Market Drivers, 2011 22
Figure 11: Emerging Pharmaceutical Market - Czech Republic, Market Restraints, 2011 23
Figure 12: Emerging Pharmaceutical Market - Czech Republic, Industry Analysis, 2011 24
Figure 13: Emerging Pharmaceutical Market - Czech Republic, Population Age Structure Forecast of Czech Republic ,Thousands, 2005 - 2050 25
Figure 14: Emerging Pharmaceutical Market - Czech Republic, Population by Gender, Thousands, 2000 - 2009 27
Figure 15: Emerging Pharmaceutical Market - Czech Republic, Life Expectancy, Years, 2000 - 2010 28
Figure 16: Emerging Pharmaceutical Market - Czech Republic, Infant Mortality Rate (Number of deaths/1,000 live births) 2000 - 2010 29
Figure 17: Emerging Pharmaceutical Market - Czech Republic, Number of Deaths by Major Diseases (%), 2010 30
Figure 18: Emerging Pharmaceutical Market - Czech Republic, Population Forecast for Cardiovascular Diseases (‘000), 2010-2018 31
Figure 19: Emerging Pharmaceutical Market - Czech Republic, Population Forecast for Cancer (‘000), 2010-2018 32
Figure 20: Emerging Pharmaceutical Market - Czech Republic, Population Forecast for Respiratory Diseases (‘000), 2010-2018 33
Figure 21: Emerging Pharmaceutical Market - Czech Republic, Population Forecast for Diabetes (‘000), 2010-2018 34
Figure 22: Emerging Pharmaceutical Market - Czech Republic, GDP at Market Prices, $bn, 2005-2010 35
Figure 23: Emerging Pharmaceutical Market - Czech Republic, GDP Composition by Sector, 2010 36
Figure 24: Emerging Pharmaceutical Market - Czech Republic, GDP and Inflation Rates in Czech Republic, 2005 - 2011 37
Figure 25: Emerging Pharmaceutical Market - Czech Republic, Average Exchange Rates, CZK, 2005 - 2011 38
Figure 26: Emerging Pharmaceutical Market - Czech Republic, Per Capita Income, $, 2000 - 2010 39
Figure 27: Emerging Pharmaceutical Market - Czech Republic, National Healthcare Expenditure, % of GDP, 2010 40
Figure 28: Emerging Pharmaceutical Market - Czech Republic, Healthcare Expenditure, $bn, 2000-2010 41
Figure 29: Emerging Pharmaceutical Market - Czech Republic, Healthcare Establishments Distribution (%), 2010 43
Figure 30: Emerging Pharmaceutical Market - Czech Republic, Public and Private Healthcare Establishments and Professionals Distribution, %, 2010 44
Figure 31: Emerging Pharmaceutical Market - Czech Republic, Healthcare Professionals, Czech Republic (%), 2010 45
Figure 32: Emerging Pharmaceutical Market - Czech Republic, Bed Care in Hospitals by Department, %, 2010 46
Figure 33: Emerging Pharmaceutical Market - Czech Republic, Health Insurance Coverage on Healthcare Expenditure, $m, 2006- 2010 49
Figure 34: Emerging Pharmaceutical Market - Czech Republic, Clinical Trials and New Drug Approval Process,2011 52
Figure 35: Emerging Pharmaceutical Market - Czech Republic, Clinical Trial Applications Assessed by Phase (%), 2010 53
Figure 36: Emerging Pharmaceutical Market - Czech Republic, Clinical Trials Assessed by Therapeutic Areas (%), 2010 54
Figure 37: Emerging Pharmaceutical Market - Czech Republic, Regulatory authorities of State Institute for Drug Control, Czech Republic. 55
Figure 38: Emerging Pharmaceutical Market - Czech Republic, MandA Deals by Year, 2009 - 2011 56
Figure 39: Emerging Pharmaceutical Market - Czech Republic, MandA Deals by Type, 2009 - 2011 57
Figure 40: Emerging Pharmaceutical Market - Czech Republic, Acquisition Deals by Type, 2009 - 2011 57
Figure 41: Emerging Pharmaceutical Market - Czech Republic, MandA Deals by Value, $m, 2009 - 2011 58
Figure 42: Emerging Pharmaceutical Market - Czech Republic, Licensing Deals by Year, 2009 - 2011 60
Figure 43: Emerging Pharmaceutical Market - Czech Republic, Quintiles, Company Profile, 2011 62
Figure 44: Emerging Pharmaceutical Market - Czech Republic, PPD, Company Profile, 2011 64
Figure 45: Emerging Pharmaceutical Market - Czech Republic, Covance, Company Profile, 2011 65
Figure 46: Emerging Pharmaceutical Market - Czech Republic, INC Research, Company Profile, 2011 66
Figure 47: Emerging Pharmaceutical Market - Czech Republic, PARAXEL, Company Profile, 2011 67
Figure 48: Emerging Pharmaceutical Market - Czech Republic, Chiltren, Company Profile, 2011 68
Figure 49: Emerging Pharmaceutical Market - Czech Republic, MEDPACE, Company Profile, 2011 69
Figure 50: Emerging Pharmaceutical Market - Czech Republic, Pra, Company Profile, 2011 70
Figure 51: Emerging Pharmaceutical Market - Czech Republic, CEPHA, Company Profile, 2011 71
Figure 52: Emerging Pharmaceutical Market - Czech Republic, KCR, Company Profile, 2011 72
Figure 53: Emerging Pharmaceutical Market - Czech Republic, A-pharma, Company Profile, 2011 73
Figure 54: Emerging Pharmaceutical Market - Czech Republic, EastHORN, Company Profile, 2011 74
Figure 55: Emerging Pharmaceutical Market - Czech Republic, Prague Clinical Services, Company Profile, 2011 75
Figure 56: Emerging Pharmaceutical Market - Czech Republic, PHARMNET, Company 76



Companies mentioned
Quintiles
PPD
Covance
Inc Research
PAREXEL
Chiltern
MEDPACE
PRA International
CEPHA
KCR
A-Pharma
EastHORN
Prague Clinical Services
PHARMNET

View This Report »

Find all the market research you need - instantly, in one place.

+1.2 Million Research Documents & Statistics +200,000 Trusted Public Sources 350 Industries With Global Coverage

24/7 Customer Support

Talk to Amrita

+1 718 303 2019

Purchase Reports From Reputable Market Research Publishers

Innovations in Home Medical Devices and Integrated Care Systems (Technical Insights)

Innovations in Home Medical Devices and Integrated Care Systems (Technical Insights)

  • $ 6 500
  • Industry report
  • June 2014
  • by Frost & Sullivan

Emerging Healthcare Delivery Models Integrated healthcare (IHC) is the design, management and delivery of healthcare services along the continuum of care. IHC is a growing trend is fast encompassing diagnosis, ...

Healthcare Workforce Management Systems Market by Solution (Talent Management, Time & Attendance, Scheduling, Optimization Services), by Mode of Delivery (Cloud-based, Web-based), by End-User (Hospital, Long Term Care) - Global Forecast to 2019

Healthcare Workforce Management Systems Market by Solution (Talent Management, Time & Attendance, Scheduling, Optimization Services), by Mode of Delivery (Cloud-based, Web-based), by End-User (Hospital, Long Term Care) - Global Forecast to 2019

  • $ 4 650
  • Industry report
  • August 2014
  • by MarketsandMarkets

The global healthcare workforce management systems market is expected to grow at a double digit CAGR during the forecast period of 2014 to 2019 and is estimated to be worth $1,453.8 million by 2019. The ...

ICT investment trends in healthcare - Enterprise ICT spending patterns through to the end of 2015

ICT investment trends in healthcare - Enterprise ICT spending patterns through to the end of 2015

  • $ 2 995
  • Industry report
  • September 2014
  • by Kable

Summary This report presents the findings from a survey of 173 healthcare providers regarding their Information & Communications Technology (ICT) investment trends. The survey investigates how healthcare ...

Global Healthcare Providers

June 2014 $ 350

ReportLinker is an award-winning market research solution that finds, filters and organizes the latest industry data so you get all the market research you need - quickly, in one place.